Literature DB >> 15320912

Interleukin-16 expression and release in bullous pemphigoid.

A Frezzolini1, G Cianchini, M Ruffelli, S Cadoni, P Puddu, O De Pità.   

Abstract

Cutaneous infiltration of activated CD4(+) T cells and eosinophils is an early event in blister formation during bullous pemphigoid (BP), suggesting that the trafficking of circulating leucocytes through the sites of inflammation, their activation and cytokine release is crucial in the pathogenesis of the disease. IL-16 is a major chemotactic factor able to recruit CD4(+) cells in the skin during inflammation and to induce the expression of functional high-affinity interleukin (IL)-2 receptors, thus contributing to cellular activation and proliferation. We performed a study in order to evaluate the presence of IL-16 in skin samples and sera and blister fluids of patients affected with BP in active phase of the disease (n = 39), compared with healthy donors studied as control group. Ten patients were also evaluated before and after steroid therapy. Our results demonstrated that IL-16 was expressed strongly by keratinocytes and by dermal infiltrating CD4(+) T lymphocytes in lesional skin of BP patients. High levels of IL-16 were detected in sera and blisters of BP, significantly higher in respect to healthy donors. When patients were investigated for the presence of eosinophil cationic protein (ECP) and soluble CD30 (sCD30) to reveal signs of eosinophils and Th2-cells activation, we found a positive correlation between IL-16 serum levels and both ECP and sCD30, suggesting that IL-16 is involved in Th2 lymphocytes and eosinophils recruitment during BP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15320912      PMCID: PMC1809150          DOI: 10.1111/j.1365-2249.2004.02570.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma.

Authors:  S Laberge; S Pinsonneault; E M Varga; S J Till; K Nouri-Aria; M Jacobson; W W Cruikshank; D M Center; Q Hamid; S R Durham
Journal:  J Allergy Clin Immunol       Date:  2000-08       Impact factor: 10.793

2.  Increased coexpression of eotaxin and interleukin 5 in bullous pemphigoid.

Authors:  M Shrikhande; T Hunziker; L R Braathen; W J Pichler; C A Dahinden; N Yawalkar
Journal:  Acta Derm Venereol       Date:  2000 Jul-Aug       Impact factor: 4.437

Review 3.  Humoral and cellular autoimmunity in autoimmune bullous skin disorders.

Authors:  M Hertl
Journal:  Int Arch Allergy Immunol       Date:  2000-06       Impact factor: 2.749

4.  Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes.

Authors:  N L Mathy; W Scheuer; M Lanzendörfer; K Honold; D Ambrosius; S Norley; R Kurth
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

Review 5.  Interleukin-16.

Authors:  W W Cruikshank; H Kornfeld; D M Center
Journal:  J Leukoc Biol       Date:  2000-06       Impact factor: 4.962

6.  Mononuclear cell infiltrates in bullous disease.

Authors:  M S Nestor; A J Cochran; A R Ahmed
Journal:  J Invest Dermatol       Date:  1987-02       Impact factor: 8.551

Review 7.  [New aspects on the pathogenesis of bullous pemphigoid].

Authors:  E Schmidt; E B Bröcker; D Zillikens
Journal:  Hautarzt       Date:  2000-09       Impact factor: 0.751

8.  Interleukin 16 expression in relation to disease activity in rheumatoid arthritis.

Authors:  S Blaschke; H Schulz; G Schwarz; V Blaschke; G A Müller; M Reuss-Borst
Journal:  J Rheumatol       Date:  2001-01       Impact factor: 4.666

9.  Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia.

Authors:  M Wakugawa; K Nakamura; H Hino; K Toyama; N Hattori; H Okochi; H Yamada; K Hirai; K Tamaki; M Furue
Journal:  Br J Dermatol       Date:  2000-07       Impact factor: 9.302

10.  Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay.

Authors:  R Eming; L Büdinger; R Riechers; O Christensen; H Bohlen; R Kalish; M Hertl
Journal:  Br J Dermatol       Date:  2000-12       Impact factor: 9.302

View more
  13 in total

1.  Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity.

Authors:  S Ajdary; F Riazi-Rad; R Jafari-Shakib; M Mohebbali
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases.

Authors:  A V Marzano; A Tedeschi; E Berti; D Fanoni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

3.  Pemphigus vulgaris immunoglobulin G can recognize a 130 000 MW antigen other than desmoglein 3 on peripheral blood mononuclear cell surface.

Authors:  Nicola Cirillo; Fernando Gombos; Alessandro Lanza
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

4.  Coagulation activation in autoimmune bullous diseases.

Authors:  A V Marzano; A Tedeschi; D Spinelli; D Fanoni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

5.  Integrative omics approach identifies interleukin-16 as a biomarker of emphysema.

Authors:  Russell P Bowler; Timothy M Bahr; Grant Hughes; Sharon Lutz; Yu-Il Kim; Christopher D Coldren; Nichole Reisdorph; Katerina J Kechris
Journal:  OMICS       Date:  2013-10-19

6.  Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease.

Authors:  A V Marzano; A Tedeschi; I Polloni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

7.  Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis Patients in Correlation with Clinical Severity of the Disease.

Authors:  Dorota Purzycka-Bohdan; Aneta Szczerkowska-Dobosz; Monika Zablotna; Justyna Wierzbicka; Anna Piotrowska; Michal A Zmijewski; Boguslaw Nedoszytko; Roman Nowicki
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

8.  Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis.

Authors:  K Juczynska; A Wozniacka; E Waszczykowska; M Danilewicz; M Wagrowska-Danilewicz; J Wieczfinska; R Pawliczak; A Zebrowska
Journal:  Mediators Inflamm       Date:  2017-10-24       Impact factor: 4.711

9.  Sarcoptes scabiei mites modulate gene expression in human skin equivalents.

Authors:  Marjorie S Morgan; Larry G Arlian; Michael P Markey
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 10.  The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease.

Authors:  Kyle T Amber; Manuel Valdebran; Khalaf Kridin; Sergei A Grando
Journal:  Front Med (Lausanne)       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.